NCT06270108View on ClinicalTrials.gov

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Treatment-resistant SchizophreniaTreatment-responsive SchizophreniaHealthy Controls
Interventions
DRUG

Riluzole

50mg twice daily (100mg total daily) for 56 days.

Trial Locations (1)

SE5 8AB

RECRUITING

Institute of Psychiatry, Psychology and Neuroscience, London

All Listed Sponsors
collaborator

South London and Maudsley NHS Foundation Trust

OTHER

lead

King's College London

OTHER